Literature DB >> 12793914

Heliox versus oxygen for nebulized aerosol therapy in children with lower airway obstruction.

Jefferson P Piva1, Sérgio S Menna Barreto, Flávio Zelmanovitz, Sérgio Amantéa, Peter Cox.   

Abstract

OBJECTIVE: To compare the distribution of an inhaled labeled radioaerosol (diethilenotriaminopenthacetate labeled with technetium-99m) when either oxygen or heliox was used as a gas vehicle of nebulization.
DESIGN: Randomized, double-blind, controlled study.
SETTING: Nuclear medicine imagining department of tertiary university-affiliated hospital. PATIENTS: Twenty children (5-15 yrs old) with confirmed diagnosis of chronic lower airway obstruction and referred for a ventilatory scintigraphy study. INTERVENTION: Patients were randomized to use either the heliox mixture (helium/oxygen, 80:20) or oxygen during the scintigraphy study. The maximal cumulative irradiation absorbed by the lungs and the slope of the curve of the cumulative irradiation incorporated into the lungs over the time were used to compare the groups. Student's t -test, one-way analysis of variance, chi-square test, and Fisher's exact test were used to compare the groups.
MEASUREMENTS AND MAIN RESULTS: Ten patients were allocated to each group with no differences in demographic data, main diagnosis, and pulmonary function tests. Ninety-five percent of the particles produced by both gases had a diameter <2.4 micro. The heliox group showed a higher slope of the irradiation incorporated curve (p <.05) than the oxygen group. When broken down into groups, these changes were more significant in those patients classified by the pulmonary function tests as having severe lower airway obstruction. They showed higher cumulative lung irradiation (p =.045) and better slope of the irradiation incorporated curve (p =.017) when heliox rather than oxygen was used as a vehicle for the diethilenotriaminopenthacetate labeled with technetium-99m. Nevertheless, in those patients with mild lower airway obstruction, heliox did not show any advantage over oxygen in the distribution the radioaerosol into the lungs.
CONCLUSION: Related to its physical properties, heliox gas seems to have a strong and pronounced effect when used in patients with severe lower airway obstruction. However, in the absence of severe lower airway obstruction, there is no advantage to using heliox instead of oxygen as a vehicle of nebulization.

Entities:  

Year:  2002        PMID: 12793914     DOI: 10.1097/00130478-200201000-00002

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  5 in total

1.  Aerosol deposition in the human lung periphery is increased by reduced-density gas breathing.

Authors:  Jonathan B Peterson; G Kim Prisk; Chantal Darquenne
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2008-06       Impact factor: 2.849

2.  Regional Ventilation and Aerosol Deposition with Helium-Oxygen in Bronchoconstricted Asthmatic Lungs.

Authors:  Elliot Eliyahu Greenblatt; Tilo Winkler; Robert Scott Harris; Vanessa Jane Kelly; Mamary Kone; Ira Katz; Andrew Martin; George Caillibotte; Dean R Hess; Jose G Venegas
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-01-29       Impact factor: 2.849

3.  Effect of heliox- and air-driven nebulized bronchodilator therapy on lung function in patients with asthma.

Authors:  Mohamad F El-Khatib; Ghassan Jamaleddine; Nadim Kanj; Salah Zeineddine; Hassan Chami; Imad Bou-Akl; Ahmad Husari; Marwan Alawieh; Pierre Bou-Khalil
Journal:  Lung       Date:  2014-03-19       Impact factor: 2.584

4.  Helium-oxygen mixture: clinical applicability in an intensive care unit.

Authors:  Milena Siciliano Nascimento; Érica Santos; Cristiane do Prado
Journal:  Einstein (Sao Paulo)       Date:  2018-11-08

Review 5.  Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned.

Authors:  Federico Bianco; Fabrizio Salomone; Ilaria Milesi; Xabier Murgia; Sauro Bonelli; Elena Pasini; Raffaele Dellacà; Maria Luisa Ventura; Jane Pillow
Journal:  Respir Res       Date:  2021-02-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.